Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
Delayed Japan Exchange  -  01:00 2022-12-06 am EST
1050.00 JPY   +0.67%
12/01Sumitomo Pharma Announces Transfer of Shares of a Consolidated Subsidiary, Sumitomo Pharma Food & Chemical
AQ
11/30MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).
CI
11/22Sumitomo Dainippon Pharma : GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sumitomo Pharma Selected for Inclusion as a Constituent of Five GPIF-Adopted ESG Indexes that Cover Japanese Stocks

08/31/2022 | 07:54am EST

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that it has been selected for inclusion as a constituent in all the ESG indexes that cover Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

The five indexes in which the Company was selected for inclusion as a constituent are the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN), and the S&P/JPX Carbon Efficient Index.

In addition to the above indexes adopted by GPIF, Sumitomo Pharma has been selected for inclusion (as a constituent) in the FTSE4Good Index Series, a leading ESG investment index, for 20 consecutive years since 2003.

Corporate Mission of Sumitomo Pharma is 'To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.' Sumitomo Pharma defines the implementation of this Corporate Mission as 'CSR-Based Management.' Sumitomo Pharma will continue to promote CSR-based management and aim at the sustained enhancement of corporate value.

About five ESG indexes that cover Japanese stocks adopted by GPIF

FTSE Blossom Japan Index The FTSE Blossom Japan Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

FTSE Blossom Japan Sector Relative Index The FTSE Blossom Japan Sector Relative Index is created by the global index provider FTSE Russell (U.K.) to measure the performance of Japanese companies demonstrating strong Environmental, Social and Governance (ESG) practices in each sector. Sumitomo Pharma has been continuously included as a constituent in the Index since 2022 when the Index was launched.

MSCI Japan ESG Select Leaders Index The MSCI Japan ESG Select Leaders Index targets 50% of the free float-adjusted market capitalization of each Global Industry Classification Standard (GICS) Sector and is designed to target companies that have high Environmental, Social and Governance (ESG) performance. Sumitomo Pharma has been continuously included as a constituent in the Index since 2017 when the Index was launched.

MSCI Japan Empowering Women Index (WIN) The MSCI Japan Empowering Women Index (WIN) aims to represent the performance of companies that are leading within their GICS sector groups in terms of promoting and maintaining gender diversity while also meeting certain quality factor criteria. Sumitomo Pharma included as a constituent in the Index in 2017, 2019, 2020, 2021 and 2022.

S&P/JPX Carbon Efficient Index The S&P/JPX Carbon Efficient Index is an ESG index jointly designed by S&P Dow Jones Indices and Japan Exchange Group. This index comprises companies included in the Tokyo Stock Price Index (TOPIX), and the weight of constituent is determined by carbon efficiency (Carbon emissions per unit of revenue) and the disclosure status of environmental information. Sumitomo Pharma is evaluated as the carbon efficiency decile classification is '2', and the carbon disclosure status is 'Disclosed.'

About FTSE4Good Index Series

The FTSE4Good Index Series is created by the global index provider FTSE Russell (U.K.) to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. Transparent management and clearlydefined ESG criteria make FTSE4Good indexes suitable tools to be used by a wide variety of market participants when creating or assessing sustainable investment products. Sumitomo Pharma has been continuously included as a constituent in the Index series since 2003.

Contact:

Tel: +81-6-6203-1407

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
JAPAN EXCHANGE GROUP, INC. -0.95% 1937 Delayed Quote.-22.34%
MSCI, INC. -1.55% 496.57 Delayed Quote.-17.66%
SUMITOMO CHEMICAL CO LTD 0.62% 490 Delayed Quote.-10.15%
SUMITOMO DAINIPPON PHARMA CO., LTD. 0.67% 1050 Delayed Quote.-21.28%
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
12/01Sumitomo Pharma Announces Transfer of Shares of a Consolidated Subsidiary, Sumitomo Pha..
AQ
11/30MediPal Holdings Corporation (TSE:7459) entered into a..
CI
11/22Sumitomo Dainippon Pharma : GARDP and Sumitomo Pharma announce partnership in search for n..
PU
11/17Sumitomo Dainippon Pharma : Nov. 01, 2022 Investors Meeting Presentation for Q2 FY2022 tra..
PU
11/01Nikkei 225 Up 0.3% on Earnings Season, Fed Outlook
MT
11/01Japanese shares end higher on positive earnings; Toyota falls
RE
11/01Transcript : Sumitomo Pharma Co., Ltd., Q2 2023 Earnings Call, Nov 01, 2022
CI
10/31Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year En..
CI
10/25Buying Spree Pulls Up Japanese Stocks; Sumitomo Pharma Unit to Buy Remaining 48% of Myo..
MT
10/25Sumitomo Pharma Unit to Acquire Remaining 48% of Myovant Sciences for $1.7 Billion
MT
More news
Financials
Sales 2023 572 B 4 187 M 4 187 M
Net income 2023 12 327 M 90,3 M 90,3 M
Net Debt 2023 27 896 M 204 M 204 M
P/E ratio 2023 29,1x
Yield 2023 2,67%
Capitalization 417 B 3 056 M 3 056 M
EV / Sales 2023 0,78x
EV / Sales 2024 1,07x
Nbr of Employees 6 987
Free-Float 41,3%
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Last Close Price 1 050,00 JPY
Average target price 1 031,43 JPY
Spread / Average Target -1,77%
EPS Revisions
Managers and Directors
Hiroshi Nomura President, Chief Executive Officer & Director
Masayo Tada Chairman
Yoshiharu Ikeda Director, Head-Research & Technology
Isao Shimizu Executive Officer & Senior Research Director
Kenji Ueno Executive Officer & GM-Technology Research
Sector and Competitors
1st jan.Capi. (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.-21.28%3 037
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.21.08%289 331
NOVO NORDISK A/S22.53%287 688
PFIZER, INC.-13.78%285 774